TG Therapeutics Ownership
TGTX Stock | USD 33.36 0.01 0.03% |
Shares in Circulation | First Issued 1996-03-31 | Previous Quarter 159.4 M | Current Value 160.7 M | Avarage Shares Outstanding 37.6 M | Quarterly Volatility 50.6 M |
TGTX |
TGTX Stock Ownership Analysis
About 67.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.1. TG Therapeutics had not issued any dividends in recent years. The entity had 100:5625 split on the 30th of April 2012. TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. Tg Therapeuticscmn operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people. To find out more about TG Therapeutics contact Michael Esq at 212 554 4484 or learn more at https://www.tgtherapeutics.com.TGTX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as TG Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TG Therapeutics backward and forwards among themselves. TG Therapeutics' institutional investor refers to the entity that pools money to purchase TG Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Deep Track Capital, Lp | 2024-09-30 | 1.7 M | Bank Of America Corp | 2024-09-30 | 1.7 M | Hood River Capital Management Llc | 2024-09-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Fmr Inc | 2024-09-30 | 1.2 M | 683 Capital Management Llc | 2024-09-30 | 1.1 M | Two Sigma Investments Llc | 2024-09-30 | 1.1 M | Amvescap Plc. | 2024-09-30 | 918.8 K | Blackrock Inc | 2024-09-30 | 22 M | Vanguard Group Inc | 2024-09-30 | 15.4 M |
TG Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TG Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TG Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TG Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
TG Therapeutics Outstanding Bonds
TG Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TG Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TGTX bonds can be classified according to their maturity, which is the date when TG Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
TOPTB 35 17 OCT 49 Corp BondUS88323AAE29 | View | |
TOPTB 5375 20 NOV 48 Corp BondUS88323AAD46 | View | |
TOPTB 375 18 JUN 50 Corp BondUS88323AAH59 | View | |
TEXTRON INC 3875 Corp BondUS883203BV22 | View | |
TEXTRON INC 3375 Corp BondUS883203BY60 | View | |
TEXTRON INC 365 Corp BondUS883203BX87 | View | |
TEXTRON INC 4 Corp BondUS883203BW05 | View | |
US883203CC32 Corp BondUS883203CC32 | View |
TG Therapeutics Corporate Filings
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8th of January 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.